Research stack

PT-141 + Melanotan II Melanocortin Research Stack

Layered melanocortin agonist protocol for arousal and pigmentation research.

Component peptides

A cyclic heptapeptide melanocortin-receptor agonist studied in sexual-health research and approved in the United States under the brand name Vyleesi for a specific indication.

Melanotan-II

A cyclic heptapeptide analog of alpha-melanocyte stimulating hormone that has been characterised in the pigmentation-research literature. Precursor to the marketed melanocortin-4 agonist bremelanotide.

Goal

Layered melanocortin-agonist protocol for arousal and pigmentation research.

Peptides

PT-141, Melanotan II

Why it works

Selective MC4R agonism by PT-141 drives central arousal pathways while broader melanocortin activation by Melanotan II adds MC1R-mediated pigmentation and additive MC4R signal.

How to use

PT-141 — 1.75 mg subcutaneous on demand.
Melanotan II — 250-500 mcg subcutaneous daily for a 1-2 week loading phase, then 500 mcg 1-2x weekly maintenance.

Last updated: 2026-09-15

Component peptides	PT-141 + Melanotan-II
Duration reported	4 weeks
Cycle pattern	PT-141 on demand; Melanotan II tapered loading then maintenance
Difficulty	advanced
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.